Stingray Bio

Stingray Bio is a preclinical-stage biotechnology company focused on the development of novel small molecule inhibitors for cancer therapy. The company's research centers on targeting the PIM kinase family and the eukaryotic translation initiation factor 4E (eIF4E), both of which play pivotal roles in tumor cell survival and resistance to standard treatments. By developing highly selective inhibitors, Stingray Bio aims to address unmet needs in patients with solid tumors and hematological malignancies. The company is headquartered at the Pennsylvania Biotechnology Center and is led by an experienced management team with a track record in oncology drug discovery.